RSS Feed
November 13th, 2021 
Awake Goy Whitney Webb writes:
“COVID-19 erased the regulatory and trial-related hurdles that [biotech/vaccine] manufacturer Moderna could never surmount before… Key issues for the company, including seemingly insurmountable regulatory hurdles and its inability to advance beyond animal trials with its most promising—and profitable—products, were conveniently wiped away, and not a moment too soon. Since January 2020, the value of Moderna’s stock—which had embarked on a steady decline since its IPO—grew from $18.89 per share to its current value of $339.57 per share, thanks to the success of its COVID-19 vaccine…”
Related posts:
France becomes third country in western Europe to pass 100,000 COVID deaths milestone
Swedish university wants to test-compare Covid vaccines’ effectiveness on population of ENTIRE REGIO...
US Supreme Court says Pfizer, Moderna may OWN Your Genes once you're Injected
Researcher Michael Swifte on draconian covid policies in Australia
Pfizer, Moderna COVID-19 Vaccines Highly Effective After First Shot in Real-World Use
Australian Truck Drivers Plan to ‘Block Every Highway’ in COVID-19 Protest
Views: 0
Posted in 
Tags: 
